RMD vs SOLV vs BSX Stock Comparison

Resmed, Solventum and Boston Scientific Prices as of Nov 13, 2026 Peers: Industry group
RMD Resmed Inc
$239.53 +1.7% 1M -5.0% 1Y
Market cap
$34.59B
P/E
21.7x
Revenue (TTM)
$5.73B
Div. yield
–
Medical Devices Healthcare
5 wins
SOLV Solventum Corp
$89.05 +2.0% 1M +18.4% 1Y
Market cap
$15.27B
P/E
97.9x
Revenue (TTM)
$8.16B
Div. yield
–
Medical Devices Healthcare
3 wins
BSX Boston Scientific Corp
$44.34 +3.1% 1M -57.8% 1Y
Market cap
$64.09B
P/E
18.3x
Revenue (TTM)
$21.07B
Div. yield
–
Medical Devices Healthcare
3 wins

Head to Head

11 decided of 12

Resmed leads on 5 of the 12 questions below (Resmed 5, Boston Scientific 3, Solventum 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionRMDSOLVBSXLeader
Larger companyMarket capitalisation $34.59B $15.27B $64.09B BSX
Cheaper on earningsLower P/E, profitable companies only 21.7x 97.9x 18.3x BSX
Cheaper on forward earningsLower price / next fiscal year consensus EPS 18.5x 12.8x 14.5x SOLV
Faster revenue growthRevenue growth, trailing twelve months +9.0% -2.8% +8.9% RMD
More profitableNet margin, trailing twelve months 27.8% 1.9% 16.6% RMD
Better return on capitalReturn on invested capital 22.0% 4.2% 9.9% RMD
Less leveragedLower net debt / EBITDA -0.3x 4.7x 2.1x RMD
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -5.0% +18.4% -57.8% SOLV
Better 5-year returnAnnualised price return, 5 years -1.2%/yr — +1.1%/yr BSX
Less volatileAnnualised volatility, 1 year 31.1% 30.1% 41.5% SOLV
Higher overall scoreMean of the five percentile scores vs peers 80/100 51/100 68/100 RMD

Percentile Scorecard

RMDSOLVBSX

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisRMDSOLVBSX
Valuation 75 #62 of 243 70 #74 of 243 87 #33 of 243
Growth 60 #92 of 228 3 #221 of 228 68 #73 of 228
Profitability 99 #3 of 222 71 #66 of 222 91 #20 of 222
Financial Health 76 #61 of 248 15 #210 of 248 43 #142 of 248
Shareholder Returns 89 #18 of 158 94 #10 of 158 48 #82 of 158
Overall 80 51 68
  • RMD ranked among 252 companies in Medical Devices and Diagnostics
  • SOLV ranked among 252 companies in Medical Devices and Diagnostics
  • BSX ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodRMDSOLVBSXSPY
1 month +1.7%+2.0%+3.1% -2.0%
3 months +6.7%+0.5%-14.5% -2.8%
6 months +18.6%+19.9%-15.8% +2.0%
Year to date -0.6%+12.4%-53.5% +10.6%
1 year -5.0%+18.4%-57.8% +12.2%
3 years +62.6%—-17.9% +68.1%
3 years, per year +17.6%—-6.4% +18.9%
5 years -6.0%—+5.4% +61.4%
5 years, per year -1.2%—+1.1% +10.1%
10 years +300.2%—+106.2% +248.5%
10 years, per year +14.9%—+7.5% +13.3%

Risk

MeasureRMDSOLVBSXSPY
Volatility, 1Y 31.1%30.1%41.5% 13.6%
Downside volatility, 1Y 33.9%29.3%47.7% 13.9%
Beta vs S&P 500, 1Y 0.510.610.26 1.00
Return / volatility, 1Y -0.160.61-1.39 0.90
Max drawdown, 5Y -49.8%-40.0%-61.6% -25.4%
From 52-week high -13.2%-3.7%-57.8% -3.2%
52-week high $275.96$92.45$104.98 $779.14
52-week low $182.82$62.49$41.57 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleRMDSOLVBSX
P/E now vs peer median 21.5xmedian 26.5x 97.5xmedian 26.5x 18.3xmedian 26.5x
P/S now vs peer median 5.9xmedian 2.7x 1.9xmedian 2.7x 3.1xmedian 2.7x
EV/EBITDA now vs peer median 15.8xmedian 18.4x 20.3xmedian 18.4x 14.1xmedian 18.4x
P/FCF now vs peer median 20.9xmedian 25.4x 156.0xmedian 25.4x 19.3xmedian 25.4x
P/B now vs peer median 5.7xmedian 2.5x 3.1xmedian 2.5x 2.5xmedian 2.5x
PEG now vs peer median 0.99median 0.98 —median 0.98 0.42median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsRMDSOLVBSX
Revenue $5.73B $8.16B $21.07B
Gross profit $3.50B $4.47B $14.57B
Operating income $1.89B $454.00M $3.93B
Net income $1.59B $156.00M $3.49B
Free cash flow $1.61B – $3.33B
R&D $393.82M $723.00M $2.16B
EPS (diluted) $11.11 $0.91 $2.41
Cash & equivalents $1.01B $451.00M $609.00M
Total debt $409.60M $5.07B $11.95B
Shares (diluted) 143.41M 170.80M 1.45B
Enterprise value $29.03B $12.98B $59.52B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricRMDSOLVBSX
P/E 21.5x 97.5x 18.3x
P/FCF 20.9x 156.0x 19.3x
P/Operating cash flow 19.0x 48.8x 15.2x
P/S 5.9x 1.9x 3.1x
P/B 5.7x 3.1x 2.5x
P/Tangible book 6.1x 6.1x 3.4x
EV/EBITDA 15.8x 20.3x 14.1x
EV/EBIT 17.5x 43.5x 19.2x
EV/Revenue 5.8x 2.4x 3.6x
EV/FCF 20.6x – 22.7x
EV/Operating cash flow 18.7x 63.7x 17.9x
PEG (3Y EPS CAGR) 0.99 – 0.42

Growth

14 metrics
MetricRMDSOLVBSX
Revenue growth (1Y) 9.0% -2.8% 8.9%
Revenue CAGR (3Y) 9.4% – 15.3%
Gross profit growth (1Y) 11.0% -1.6% 9.8%
Gross profit CAGR (3Y) 13.2% – 15.1%
Operating income growth (1Y) 8.5% -79.3% 13.5%
Operating income CAGR (3Y) 18.2% – 22.1%
Net income growth (1Y) 10.8% -89.8% 25.5%
Net income CAGR (3Y) 20.7% – 41.7%
EPS growth (1Y) 13.5% -89.5% 29.2%
EPS CAGR (3Y) 21.8% – 44.0%
Operating cash flow growth (1Y) -6.0% -37.1% -8.5%
Operating cash flow CAGR (3Y) 23.7% – 21.6%
Free cash flow growth (1Y) -9.0% – -12.9%
Free cash flow CAGR (3Y) 25.5% – 25.2%

Profitability

14 metrics
MetricRMDSOLVBSX
Gross margin 61.1% 54.8% 69.1%
EBITDA margin 36.4% 11.9% 25.5%
Operating margin 33.0% 5.6% 18.7%
Pretax margin 35.1% 2.1% 17.3%
Net margin 27.8% 1.9% 16.6%
FCF margin 28.1% – 15.8%
Operating cash flow margin 30.9% 3.8% 20.1%
Return on equity 25.4% 3.3% 13.7%
Return on assets 18.5% 1.1% 7.7%
Return on invested capital 22.0% 4.2% 9.9%
Return on capital employed 26.1% 4.3% 10.0%
Asset turnover 0.7x 0.6x 0.5x
Cash conversion (OCF / net income) 1.1x 2.0x 1.2x
Stock comp / revenue 2.0% 2.1% 1.5%

Financial Health

11 metrics
MetricRMDSOLVBSX
Debt / assets 5.0% 35.8% 26.3%
Debt / equity 0.1x 1.1x 0.5x
Net debt / EBITDA -0.3x 4.7x 2.1x
Debt / FCF 0.3x – 3.6x
Liabilities / assets 27.6% 66.1% 43.1%
Equity / assets 72.4% 33.9% 56.9%
Interest coverage 81.1x – 10.5x
Current ratio 2.6x 1.0x 1.4x
Quick ratio 1.5x 0.5x 0.6x
Cash ratio 0.8x 0.1x 0.1x
Altman Z-score 12.00 1.85 3.03

Shareholder Returns

7 metrics
MetricRMDSOLVBSX
Dividend yield 1.1% – –
Net buyback yield 4.2% 2.7% -0.3%
Shareholder yield 5.3% 2.7% -0.3%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusRMDSOLVBSX
Forward P/E 18.5xFY2027 12.8xFY2026 14.5xFY2026
EPS, next fiscal year $12.92FY2027 $6.93FY2026 $3.06FY2026
EPS growth, next FY +15.7%FY2027 +13.4%FY2026 0.0%FY2026
EPS growth, the year after +8.9% +15.3% +8.2%
Revenue, next fiscal year $5.99BFY2027 $7.71BFY2026 $20.48BFY2026
Revenue growth, next FY +6.0%FY2027 -7.3%FY2026 +2.1%FY2026
Revenue growth, the year after -3.8% +5.8% -4.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersRMDSOLVBSX
Held by institutions 68.7% 73.9% 90.5%
Institutions holding 889 882 1,484
Change in shares held, QoQ +3.2% -0.9% -0.7%
Institutions buying 404 370 738
Institutions selling 360 286 612
Buyers to sellers 1.12 1.29 1.21

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

RMDSOLVBSX
RMD 1.00 0.45 0.24
SOLV 0.45 1.00 0.23
BSX 0.24 0.23 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, RMD, SOLV and BSX?

Boston Scientific (BSX) is the largest by market capitalisation: Resmed (RMD) $34.59B, Solventum (SOLV) $15.27B, Boston Scientific (BSX) $64.09B.

Which stock is cheaper, RMD, SOLV and BSX?

Boston Scientific (BSX) trades on the lowest price-to-earnings ratio (Resmed (RMD) 21.7x, Solventum (SOLV) 97.9x, Boston Scientific (BSX) 18.3x). On next year's consensus earnings, Solventum (SOLV) is cheapest (Resmed (RMD) 18.5x, Solventum (SOLV) 12.8x, Boston Scientific (BSX) 14.5x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Resmed (RMD) grew revenue fastest over the trailing twelve months: Resmed (RMD) +9.0%, Solventum (SOLV) -2.8%, Boston Scientific (BSX) +8.9%.

Which company is more profitable?

Resmed (RMD) has the highest net margin (Resmed (RMD) 27.8%, Solventum (SOLV) 1.9%, Boston Scientific (BSX) 16.6%). On return on invested capital, Resmed (RMD) leads (Resmed (RMD) 22.0%, Solventum (SOLV) 4.2%, Boston Scientific (BSX) 9.9%).

Which stock has performed better?

Over the past year Solventum (SOLV) returned the most: Resmed (RMD) -5.0%, Solventum (SOLV) +18.4%, Boston Scientific (BSX) -57.8%. Over five years, Boston Scientific (BSX) compounded fastest (Resmed (RMD) -1.2%/yr, Boston Scientific (BSX) +1.1%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Solventum (SOLV) has been the steadiest (Resmed (RMD) 31.1%, Solventum (SOLV) 30.1%, Boston Scientific (BSX) 41.5%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, RMD, SOLV and BSX?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Resmed (RMD) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.